208 related articles for article (PubMed ID: 19389744)
21. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy.
Wasiak J; Hoare B; Wallen M
Cochrane Database Syst Rev; 2004 Oct; (4):CD003469. PubMed ID: 15495055
[TBL] [Abstract][Full Text] [Related]
22. Off label use of botulinum toxin in children under two years of age: a systematic review.
Druschel C; Althuizes HC; Funk JF; Placzek R
Toxins (Basel); 2013 Jan; 5(1):60-72. PubMed ID: 23296386
[TBL] [Abstract][Full Text] [Related]
23. Treating spastic equinus foot from cerebral palsy with botulinum toxin type A: what factors influence the results?: an analysis of 189 consecutive cases.
Pascual-Pascual SI; Pascual-Castroviejo I; Ruiz PJ
Am J Phys Med Rehabil; 2011 Jul; 90(7):554-63. PubMed ID: 21765274
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy.
Cardoso ES; Rodrigues BM; Barroso M; Menezes CJ; Lucena RS; Nora DB; Melo A
Pediatr Neurol; 2006 Feb; 34(2):106-9. PubMed ID: 16458821
[TBL] [Abstract][Full Text] [Related]
25. Is an instrumented spasticity assessment an improvement over clinical spasticity scales in assessing and predicting the response to integrated botulinum toxin type a treatment in children with cerebral palsy?
Bar-On L; Van Campenhout A; Desloovere K; Aertbeliën E; Huenaerts C; Vandendoorent B; Nieuwenhuys A; Molenaers G
Arch Phys Med Rehabil; 2014 Mar; 95(3):515-23. PubMed ID: 23994052
[TBL] [Abstract][Full Text] [Related]
26. Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy.
Kawano A; Yanagizono T; Kadouchi I; Umezaki T; Chosa E
J Orthop Sci; 2018 Mar; 23(2):389-393. PubMed ID: 29146092
[TBL] [Abstract][Full Text] [Related]
27. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.
Koman LA; Paterson Smith B; Balkrishnan R
Paediatr Drugs; 2003; 5(1):11-23. PubMed ID: 12513103
[TBL] [Abstract][Full Text] [Related]
28. Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review.
Reeuwijk A; van Schie PE; Becher JG; Kwakkel G
Clin Rehabil; 2006 May; 20(5):375-87. PubMed ID: 16774088
[TBL] [Abstract][Full Text] [Related]
29. [Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children].
Deleplanque B; Lagueny A; Flurin V; Arnaud C; Pedespan JM; Fontan D; Pontallier JR
Rev Chir Orthop Reparatrice Appar Mot; 2002 May; 88(3):279-85. PubMed ID: 12037484
[TBL] [Abstract][Full Text] [Related]
30. Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.
Sheean G
Drug Saf; 2006; 29(1):31-48. PubMed ID: 16454533
[TBL] [Abstract][Full Text] [Related]
31. Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study.
Franzén M; Hägglund G; Alriksson-Schmidt A
BMC Musculoskelet Disord; 2017 Dec; 18(1):520. PubMed ID: 29228927
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of a program of application of the botulinum toxin type A in children with cerebral palsy in Vale do Jequitinhonha].
Silva GF; Teles MC; Santos SA; Ferreira FO; Almeida KM; Camargos AC
Cien Saude Colet; 2013 Jul; 18(7):2075-84. PubMed ID: 23827912
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.
Koman LA; Mooney JF; Smith BP; Walker F; Leon JM
J Pediatr Orthop; 2000; 20(1):108-15. PubMed ID: 10641699
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response.
Sätilä H; Huhtala H
Am J Phys Med Rehabil; 2010 Nov; 89(11):865-72. PubMed ID: 20736816
[TBL] [Abstract][Full Text] [Related]
35. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy.
Blaszczyk I; Foumani NP; Ljungberg C; Wiberg M
Toxins (Basel); 2015 Nov; 7(11):4645-54. PubMed ID: 26561833
[TBL] [Abstract][Full Text] [Related]
36. Letter to the editor on 'Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials'.
Idrovo AJ; Albavera-Hernández C; Rodríguez JM
Clin Rehabil; 2009 Sep; 23(9):862-3. PubMed ID: 19713401
[No Abstract] [Full Text] [Related]
37. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular Botulinum toxin-A injections.
Read FA; Boyd RN; Barber LA
Res Dev Disabil; 2017 Sep; 68():35-41. PubMed ID: 28735160
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Botulinum Toxin Type A in Children With Spastic Cerebral Palsy Aged <2 Years: A Systematic Review.
Yang H; Chen S; Shen J; Chen Y; Lai M; Chen L; Fang S
J Child Neurol; 2023 May; 38(6-7):454-465. PubMed ID: 37431191
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
[TBL] [Abstract][Full Text] [Related]
40. [Botulinum toxin type A in children: evaluation of indications with a review of the literature].
Bertrand H; Forin V
Ann Readapt Med Phys; 2003 Jul; 46(6):346-52. PubMed ID: 12928142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
